Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Liabilities (2016 - 2025)

China Pharma Holdings' Total Liabilities history spans 16 years, with the latest figure at $8.3 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 15.69% year-over-year to $8.3 million; the TTM value through Dec 2025 reached $8.3 million, up 15.69%, while the annual FY2025 figure was $8.3 million, 15.69% up from the prior year.
  • Total Liabilities reached $8.3 million in Q4 2025 per CPHI's latest filing, up from $7.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $16.6 million in Q4 2021 to a low of $6.9 million in Q2 2024.
  • Average Total Liabilities over 5 years is $10.6 million, with a median of $10.3 million recorded in 2021.
  • Peak YoY movement for Total Liabilities: grew 26.83% in 2021, then plummeted 39.63% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $16.6 million in 2021, then dropped by 18.87% to $13.5 million in 2022, then plummeted by 33.2% to $9.0 million in 2023, then fell by 20.8% to $7.1 million in 2024, then grew by 15.69% to $8.3 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Total Liabilities are $8.3 million (Q4 2025), $7.5 million (Q3 2025), and $7.3 million (Q2 2025).